A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity

Borner M, Roth A, Lanz D, Brauchli P, Honegger H, Köberle D, Herrmann R, Rauch D, Saletti P, Wernli M, Popescu R, Dietrich D, Bernhard J, Swiss Group for Clinical Cancer Research (SAKK), Berne, Switzerland. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005; 16:282-8.